Cargando…
Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer
KRAS mutation is a well‐known marker for poor response to targeted treatment and patient prognosis in microsatellite stable (MSS) colorectal cancer (CRC). However, variation in clinical outcomes among patients wild‐type for KRAS underlines that this is not a homogeneous population. Here, we evaluate...
Autores principales: | Eilertsen, Ina A., Sveen, Anita, Strømme, Jonas M., Skotheim, Rolf I., Nesbakken, Arild, Lothe, Ragnhild A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587976/ https://www.ncbi.nlm.nih.gov/pubmed/30121958 http://dx.doi.org/10.1002/ijc.31809 |
Ejemplares similares
-
Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell‐intrinsic properties
por: Eide, Peter W., et al.
Publicado: (2019) -
KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer
por: Nagy, Ádám, et al.
Publicado: (2016) -
Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
por: Kimbung, Siker, et al.
Publicado: (2017) -
Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer
por: Csizmarik, Anita, et al.
Publicado: (2022) -
High hemoglobin A1c levels within the non‐diabetic range are associated with the risk of all cancers
por: Goto, Atsushi, et al.
Publicado: (2015)